Juvenile Macular Degeneration

3

Review clinical trials related to Juvenile Macular Degeneration. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Inherited Retinal Degenerative Disease Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.

Participants needed: 20,000
Trial details
Biological sex: AllType: ObservationalSponsor: Foundation Fighting BlindnessUpdated: May 19, 2026Locations: 1Duration: 20 Years
Eligibility criteria

Diagnosed with an inherited retinal degenerative disease OR

Glaucoma only [+3]

Status: Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Participants needed: 50
Trial details
Age: 5+Biological sex: AllType: ObservationalSponsor: Ascidian Therapeutics, IncUpdated: Mar 11, 2026Locations: 8
Eligibility criteria

Presence of mutations in the ABCA4 gene [+1]

The presence of pathogenic or likely pathogenic mutations in other genes known t... [+2]

Status: Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Ascidian Therapeutics, IncUpdated: Dec 2, 2025Locations: 10
Eligibility criteria

Presence of mutations in the ABCA4 gene [+3]

The presence of pathogenic or likely pathogenic mutations in other genes known t... [+2]